In last trading session, Kindred Biosciences, Inc. (NASDAQ:KIN) saw 2,583,007 shares changing hands with its beta currently measuring 1.02. Company’s recent per share price level of $4.75 trading at $0.66 or 15.6% at recent trade assigns it a market valuation of $192.13 Million. That current price of KIN’s stock is at a discount of -151.16% from its 52-week high price of $11.93 and is indicating a premium of 34.63% from its 52-week low price of $3.105. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 242.4 Million shares which gives us an average trading volume of 347.18 Million if we extend that period to 3-months.

For Kindred Biosciences, Inc. (KIN), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2. Splitting up the data highlights that, out of 8 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 7 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of $0 in the current quarter.

Kindred Biosciences, Inc. (NASDAQ:KIN) trade information

Upright in the green today for gaining 25.3%, in the last five days KIN remained trading in the green while hitting it’s week-highest on Tuesday, Jun 23 when the stock touched $4.55-7 price level, adding 7.91% to its value on the day. Kindred Biosciences, Inc.’s shares saw a change of -50.59% in year-to-date performance and have moved -3.68% in past 5-day. Kindred Biosciences, Inc. (NASDAQ:KIN) showed a performance of -12.16% in past 30-days. Number of shares sold short was 479.36 Million shares which calculate 1.38 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of $13.64 to the stock, which implies a rise of 187.16% to its current value. Analysts have been projecting $9 as a low price target for the stock while placing it at a high target of $25. It follows that stock’s current price would jump +426.32% in reaching the projected high whereas dropping to the targeted low would mean a loss of 89.47% for stock’s current value.

Kindred Biosciences, Inc. (KIN) estimates and forecasts

Statistics highlight that Kindred Biosciences, Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company lessened -49.52% of value to its shares in past 6 months, showing an annual growth rate of -20.13% while that of industry is 9.2. Apart from that, the company came raising its revenue forecast for fiscal year 2020. The company is estimating its revenue growth to increase by 100% in the current quarter and calculating 7.7% increase in the next quarter. This year revenue growth is estimated to rise 187.4% from the last financial year’s standing.

7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $12.06 Million for the same. And 7 analysts are in estimates of company making revenue of $490Million in the next quarter that will end in September 01, 2020.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -1.9% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 0.9% while estimates for its earnings growth in next 5 years are of 40%

Kindred Biosciences, Inc. (NASDAQ:KIN)’s Major holders

Insiders are in possession of 5.96% of company’s total shares while institution are holding 67.66% percent of that, with stock having share float percentage of 71.94%. Investors also watch the number of corporate investors in a company very closely, which is 104 institutions for Kindred Biosciences, Inc. that are currently holding shares of the company. Park West Asset Management LLC is the top institutional holder at KIN for having 6.74 Million shares of worth $26.98 Million. And as of March 30, 2020, it was holding 17.16% of the company’s outstanding shares.

The second largest institutional holder is Blackrock Inc., which was holding about 2.46 Million shares on March 30, 2020. The number of shares represents firm’s hold over 6.27% of outstanding shares, having a total worth of $9.85 Million.

On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of March 30, 2020, the former fund manager was holding 1127689 shares of worth $4.51 Million or 2.87% of the total outstanding shares. The later fund manager was in possession of 829.05 Thousand shares on March 30, 2020, making its stake of worth around $3.32 Million in the company or a holder of 2.11% of company’s stock.